agenusbio.com

Avaliação do site agenusbio.com

Agenus: Better immunotherapies

 Gerado a 28 de Março de 2026 02:34 AM

Estatísticas desatualizadas? ATUALIZE !

O resultado é de 54/100

Conteúdo SEO

Título

Agenus: Better immunotherapies

Cumprimento : 30

Perfeito, o Título contém entre 10 e 70 caracteres.

Descrição

Activating the Power of the Immune System to Defeat Cancer

Cumprimento : 58

Idealmente, a Descrição META deve conter entre 70 e 160 caracteres (incluíndo espaços).

Palavras-chave

Mau. Não detetámos palavras-chave META na sua página.

Propriedades Og Meta

Boa! Esta página tira vantagens das propriedades Og.

Propriedade Conteúdo
type website

Cabeçalhos

H1 H2 H3 H4 H5 H6
2 24 65 0 0 0
  • [H1] Using Your Immune System to Defeat Cancer
  • [H1] Using Your Immune System to Defeat Cancer
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
  • [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
  • [H2] Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
  • [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
  • [H2] Innovative Immunotherapies
  • [H2] Learn how our science is changing what’s possible
  • [H2] Stage III MSS Colorectal Cancer
  • [H2] Merkel Cell Carcinoma
  • [H2] Undifferentiated Pleomorphic Sarcoma
  • [H2] Bringing the Power of Immunotherapy
to More Patients
  • [H2] “30 years ago, we envisioned a future where the immune system could be harnessed to cure cancer. That vision remains our driving force today—science-led, patient-focused, and unwavering in our mission to transform outcomes.”
  • [H2] In the News
  • [H2] Get answers about clinical trials, patient access, and more
  • [H2] By the Numbers
  • [H3] OncoDaily
  • [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
  • [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
  • [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
  • [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
  • [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
  • [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
  • [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
  • [H3] Redefining Cancer Care
  • [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
  • [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
  • [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
  • [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
  • [H3] Immunotherapies break into cold colorectal cancers at ASCO
  • [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
  • [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
  • [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
  • [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
  • [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
  • [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
  • [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
  • [H3] New Strategies for Targeting CTLA-4 Emerge
  • [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
  • [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
  • [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
  • [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
  • [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
  • [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
  • [H3] Unpacking the Latest Research in Gastrointestinal Cancers
  • [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
  • [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
  • [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
  • [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer
  • [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
  • [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
  • [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
  • [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
  • [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
  • [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
  • [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
  • [H3] Redefining Cancer Care
  • [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
  • [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
  • [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
  • [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
  • [H3] Immunotherapies break into cold colorectal cancers at ASCO
  • [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
  • [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
  • [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
  • [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
  • [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
  • [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
  • [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
  • [H3] New Strategies for Targeting CTLA-4 Emerge
  • [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
  • [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
  • [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
  • [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
  • [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
  • [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
  • [H3] Unpacking the Latest Research in Gastrointestinal Cancers
  • [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
  • [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
  • [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
  • [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer

Imagens

Encontrámos 164 imagens nesta página.

164 atributos ALT estão vazios ou em falta. É recomendado adicionar texto alternativo de modo a que os motores de busca identifiquem melhor o conteúdo das suas imagens.

Rácio Texto/HTML

Rácio : 5%

O rácio de texto para código HTML desta página é menor que 15 porcento, o que significa que provavelmente é necessário de adicionar mais conteúdos em forma de texto.

Flash

Perfeito, não foi encontrado conteúdo Flash nesta página.

Iframe

Oh, não, esta página tem Iframes na página, o que significa que o conteúdo destas não pode ser indexado.

Reescrita de URL

Perfeito. As ligações aparentam ser limpas!

Underscores (traços inferiores) nas URLs

Perfeito. Não foram encontrados 'underscores' (traços inferiores) nas suas URLs.

Ligações para a própria página

Encontrámos um total de 41 ligações incluindo 0 ligações a ficheiros

Âncoras Tipo Sumo
- Internas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
- Externas Passa sumo
Opt-out preferences Internas Passa sumo
Terms and Conditions of Use Internas Passa sumo
Privacy Policy Internas Passa sumo
Community Guidelines Internas Passa sumo
Access to Investigational Medicines Policy Internas Passa sumo
Report Adverse Event Internas Passa sumo
Investor Portal Internas Passa sumo

Palavras-chave SEO

Núvem de palavras-chave

cancer agenus news patient january access balstilimab immunotherapy colorectal botensilimab

Consistência das Palavras-chave

Palavra-chave Conteúdo Título Palavras-chave Descrição Cabeçalhos
cancer 48
access 29
botensilimab 28
agenus 25
colorectal 23

Usabilidade

Url

Domínio : agenusbio.com

Cumprimento : 13

Favicon

Ótimo, o site tem um favicon.

Facilidade de Impressão

Não encontrámos CSS apropriado para impressão.

Língua

Otimo! A língua declarada deste site é en.

Dublin Core

Esta página não tira vantagens do Dublin Core.

Documento

Tipo de Documento

HTML 5

Codificação

Perfeito. O conjunto de caracteres UTF-8 está declarado.

Validação W3C

Erros : 0

Avisos : 0

Privacidade do Email

Aviso! No mínimo, foi encontrado um endereço de email sob a forma de texto. Isto é um convite para que spammers entupam a caixa de correio deste endereço.

HTML obsoleto

Fantástico! Não detetámos etiquetas HTML obsoletas.

Dicas de Velocidade

Excelente, este site não usa tablelas dentro de tabelas.
Oh não, o site usa estilos CSS nas etiquetas HTML.
Boa, o site usa poucos ficheiros CSS.
Oh, não! O site utiliza demasiados ficheiros JavaScript (mais que 6).
Perfeito, o site tira vantagens da compressão gzip.

Dispositivos Móveis

Otimização para dispositivos móveis

Icon Apple
Meta Viewport Tag
Conteúdo Flash

Otimização

XML Sitemap

Perfeito, o site tem um mapa XML do site (sitemap).

https://www.agenusbio.com/sitemap.xml

Robots.txt

https://agenusbio.com/robots.txt

Perfeito, o seu site tem um ficheiro robots.txt.

Analytics

Em falta

Não detetámos nenhuma ferramenta analítica de análise de atividade.

Este tipo de ferramentas (como por exemplo o Google Analytics) permite perceber o comportamento dos visitantes e o tipo de atividade que fazem. No mínimo, uma ferramenta deve estar instalada, sendo que em algumas situações mais do que uma pode ser útil.

PageSpeed Insights

Dispositivo
Categorias

Free SEO Testing Tool

Free SEO Testing Tool é uma ferramenta gratuita que o ajuda a avaliar o seu site